AIM: Over 30% of patients with major depression do not respond well to first-line treatment with selective serotonin reuptake inhibitors (SSRIs). Using genome-wide expression profiling of human lymphoblastoid cell lines (LCLs) CHL1 was identified as a tentative SSRI sensitivity biomarker. This study reports on miRNAs implicated in SSRI sensitivity of LCLs. METHODS: Eighty LCLs were screened from healthy adult female individuals for growth inhibition by paroxetine. Eight LCLs exhibiting high or low sensitivities to paroxetine were chosen for genome-wide expression profiling with miRNA microarrays. RESULTS: The miRNA miR-151-3p had 6.7-fold higher basal expression in paroxetine-sensitive LCLs. This corresponds with lower expression of CHL1, a target of miR-151-3p. The additional miRNAs miR-212, miR-132, miR-30b*, let-7b and let-7c also differed by >1.5-fold (p < 0.05) between the two LCL groups. CONCLUSION: The potential value of these miRNAs as tentative SSRI response biomarkers awaits validation with lymphocyte samples of major depression patients.
AIM: Over 30% of patients with major depression do not respond well to first-line treatment with selective serotonin reuptake inhibitors (SSRIs). Using genome-wide expression profiling of human lymphoblastoid cell lines (LCLs) CHL1 was identified as a tentative SSRI sensitivity biomarker. This study reports on miRNAs implicated in SSRI sensitivity of LCLs. METHODS: Eighty LCLs were screened from healthy adult female individuals for growth inhibition by paroxetine. Eight LCLs exhibiting high or low sensitivities to paroxetine were chosen for genome-wide expression profiling with miRNA microarrays. RESULTS: The miRNA miR-151-3p had 6.7-fold higher basal expression in paroxetine-sensitive LCLs. This corresponds with lower expression of CHL1, a target of miR-151-3p. The additional miRNAs miR-212, miR-132, miR-30b*, let-7b and let-7c also differed by >1.5-fold (p < 0.05) between the two LCL groups. CONCLUSION: The potential value of these miRNAs as tentative SSRI response biomarkers awaits validation with lymphocyte samples of major depressionpatients.
Authors: C Fabbri; C Crisafulli; D Gurwitz; J Stingl; R Calati; D Albani; G Forloni; M Calabrò; R Martines; S Kasper; J Zohar; A Juven-Wetzler; D Souery; S Montgomery; J Mendlewicz; G D Girolamo; A Serretti Journal: Pharmacogenomics J Date: 2015-04-07 Impact factor: 3.550
Authors: Evangelia Eirini Tsermpini; Christina I Kalogirou; George C Kyriakopoulos; George P Patrinos; Constantinos Stathopoulos Journal: Pharmacogenomics J Date: 2022-06-20 Impact factor: 3.245
Authors: Krassimira A Garbett; Andrea Vereczkei; Sára Kálmán; Jacquelyn A Brown; Warren D Taylor; Gábor Faludi; Željka Korade; Richard C Shelton; Károly Mirnics Journal: Biol Psychiatry Date: 2014-06-02 Impact factor: 13.382